MPAL.L is trading 6.9% up at $4.65 as the stock rebounds from yesterday’s pullback following a volatile stretch driven by UK regulatory news.
- The recent price action follows a sharp multi-day surge and subsequent profit-taking linked to Novo Nordisk’s oral GLP-1 product.
- With no fresh company announcements this morning, the gain appears to reflect continued momentum buying and investor repositioning after the recent approval-linked rally.